Revelation Biosciences Expands Acute Kidney Injury Advisory Board
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Update
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Viking Therapeutics (NASDAQ:VKTX) and Revelation Biosciences (NASDAQ:REVB) Head to Head Contrast
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Revelation Biosciences (NASDAQ:REVB) Shares Up 2.4% – Here’s Why
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
Revelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross Proceeds
Revelation Biosciences Inc. Announces FDA Acceptance of Gemini IND
Revelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug Supply
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024
Revelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10
How an Election Impacts Penny Stocks
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini